A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

Overview

This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism.

Full Title of Study: “A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 21, 2021

Detailed Description

Fifteen prevalent and stable hemodialysis patients with secondary hyperparathyroidism eligible for treatment with calcium receptor sensitizers according to current KDIGO will be included. Study phases will begin and end on the day of the first hemodialysis session of the week. The run-in phase will last 4 weeks. No calcimimetics will be prescribed during the run-in phase. The treatment phase starts with a dose of etelcalcetide is 2.5mg thrice weekly. Etelcalcetide dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly. The wash-out Phase starts after completion of the 15mg thrice-weekly phase or in case a pre-specified safety endpoint is reached, etelcalcetide will be discontinued and patients will be followed for additional 8 weeks to study any potential reversibility of PTH lowering on T50 results. For the individual patient, the study duration will be 9 months

Interventions

  • Drug: Etelcalcetide
    • Up-Titration

Arms, Groups and Cohorts

  • Experimental: Etelcalcetide 2.5 mg
    • Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
  • Experimental: Etelcalcetide 5 mg
    • Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
  • Experimental: Etelcalcetide 7,5 mg
    • Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
  • Experimental: Etelcalcetide 10 mg
    • Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
  • Experimental: Etelcalcetide 12,5 mg
    • Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
  • Experimental: Etelcalcetide 15 mg
    • Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly

Clinical Trial Outcome Measures

Primary Measures

  • T50-Laboratory Test for measuring calcification
    • Time Frame: 32 weeks
    • The changes in T50 values between the different study phases will be evaluated as the primary outcome.

Participating in This Clinical Trial

Inclusion Criteria

  • Prevalent patients (≥ 3 months on dialysis) treated with thrice weekly hemodialysis (HD) or hemodiafiltration (HDF) – Secondary hyperparathyroidism defined as PTH levels > 9x ULN according to current KDIGO guidelines if therapy-naïve, or patients already treated with calcium receptor sensitizers with PTH > 2x ULN – Albumin corrected calcium ≥ 2,08 mmol/l – Calcium concentrations of dialysate stable for at least 2 weeks prior to screening Exclusion Criteria:

  • Currently receiving treatment in another investigational device or drug study or participation in non-interventional studies – Current treatment with etelcalcetide (Parsabiv©) or treatment with etelcalcetide within 3 months prior to study inclusion – Patient has known sensitivity to any of the products or components of Parsabiv© – Patient has received a parathyroidectomy – Parathyroidectomy planned or expected during the study period – Elective kidney transplant scheduled during the study period – Therapy with bisphosphonates within the past 12 months – Therapy with denosumab within the past 6 months – Antacids containing aluminum, calcium, magnesium or bicarbonate – Patient has a history of symptomatic ventricular arrhythmias or Torsades de Pointes – Patient has a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening. – Pregnant or nursing (lactating) women

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Prim. Priv. Doz. Dr. Daniel Cejka
  • Collaborator
    • Amgen
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Prim. Priv. Doz. Dr. Daniel Cejka, Head of Nephrology department – Elisabethinen Hospital
  • Overall Official(s)
    • Daniel Cejka, Md, Principal Investigator, Head of Nephrology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.